PU-WS13Grp94-specific Hsp90 inhibitor CAS# 1454619-14-7 |
- Alvespimycin
Catalog No.:BCC1346
CAS No.:467214-20-6
- AUY922 (NVP-AUY922)
Catalog No.:BCC2123
CAS No.:747412-49-3
- KW-2478
Catalog No.:BCC2127
CAS No.:819812-04-9
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- PF-04929113 (SNX-5422)
Catalog No.:BCC2130
CAS No.:908115-27-5
- AT13387
Catalog No.:BCC2122
CAS No.:912999-49-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1454619-14-7 | SDF | Download SDF |
PubChem ID | 71660551 | Appearance | Powder |
Formula | C17H20Cl2N6S | M.Wt | 411.35 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 40 mg/mL (97.24 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 8-(3,5-dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine | ||
SMILES | CC(C)NCCCN1C2=C(C(=NC=N2)N)N=C1SC3=CC(=CC(=C3)Cl)Cl | ||
Standard InChIKey | JYSLFQTWNRYWJT-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H20Cl2N6S/c1-10(2)21-4-3-5-25-16-14(15(20)22-9-23-16)24-17(25)26-13-7-11(18)6-12(19)8-13/h6-10,21H,3-5H2,1-2H3,(H2,20,22,23) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PU-WS13 is a selective Grp94 inhibitor, with an EC50 of 0.22 μM.In Vitro:PU-WS13 is a Grp94 inhibitor, with an EC50 of 0.22 μM. PU-WS13 also slightly suppresses Hsp90α, Hsp90β and Trap-1, with EC50s of 27.3, 41.8 and 7.3 μM, respectively. PU-WS13 (2.5-20 μM) shows no toxicity on two nonmalignant cell lines. PU-WS13 (15 μM) disrupts the circular architecture of HER2 at the plasma membrane of SKBr3 cells mediated through Grp94. PU-WS13 inhibits Grp94, and the inhibition induces apoptosis in and reduce the viability of HER2 overexpressing breast cancer cells[1]. References: |
PU-WS13 Dilution Calculator
PU-WS13 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.431 mL | 12.1551 mL | 24.3102 mL | 48.6204 mL | 60.7755 mL |
5 mM | 0.4862 mL | 2.431 mL | 4.862 mL | 9.7241 mL | 12.1551 mL |
10 mM | 0.2431 mL | 1.2155 mL | 2.431 mL | 4.862 mL | 6.0775 mL |
50 mM | 0.0486 mL | 0.2431 mL | 0.4862 mL | 0.9724 mL | 1.2155 mL |
100 mM | 0.0243 mL | 0.1216 mL | 0.2431 mL | 0.4862 mL | 0.6078 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
The Hsp90 family of molecular chaperones regulates and maintains cell homeostasis under proteotoxic stress and pathogenic pressure. In humans, Hsp90α and Hsp90β in the cytoplasm, Grp94 in the endoplasmic reticulum and Trap-1 in the mitochondria are the four Hsp90 paralogs. PU-WS13 is a potent, Grp94-specific Hsp90 inhibitor of the purine scaffold class.
In vitro: Brief treatment of SKBr3 cells with PU-WS13 disrupted the circular architecture of HER2 at the plasma membrane, resulting in a ‘shredded’ HER2 pattern. The effect of PU-WS13 on the HER2 surface architecture is mediated through Grp94. Upon treatment of cells with PU-WS13, a rapid accumulation of cells in the sub-G1 phase, PARP cleavage and a substantial increase in markers of early- and late-stage apoptosis were noted [1].
In vivo: Potent and durable anti-tumor effects in TNBC xenografts, including complete response and tumor regression, without toxicity to the host are achieved with PUH71, a chemical analogue of PU-WS13. Notably, TNBC tumors respond to retreatment with PUH71 for several cycles extending for over 5 months without evidence of resistance or toxicity [2].
Clinical trial: Up to now, PU-WS13 is still in the preclinical development stage.
Reference:
[1] Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013 Nov;9(11):677-84.
[2] Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73.
- Isolintetralin
Catalog No.:BCN3052
CAS No.:145459-30-9
- Heterophyllin B
Catalog No.:BCN2768
CAS No.:145459-19-4
- L-692,585
Catalog No.:BCC7305
CAS No.:145455-35-2
- Homalomenol A
Catalog No.:BCN1647
CAS No.:145400-03-9
- 1,4,7-Eudesmanetriol
Catalog No.:BCN1646
CAS No.:145400-02-8
- GDC-0994
Catalog No.:BCC6371
CAS No.:1453848-26-4
- Sideroxylonal A
Catalog No.:BCN1645
CAS No.:145382-68-9
- Isochlorogenic acid B
Catalog No.:BCN5909
CAS No.:14534-61-3
- Dihydropinosylvin
Catalog No.:BCN6258
CAS No.:14531-52-3
- Bergenin pentaacetate
Catalog No.:BCN6257
CAS No.:14531-47-6
- TC-E 5002
Catalog No.:BCC5608
CAS No.:1453071-47-0
- A 77636 hydrochloride
Catalog No.:BCC7159
CAS No.:145307-34-2
- Furano(2'',3'',7,6)-4'-hydroxyflavanone
Catalog No.:BCN6405
CAS No.:1454619-70-5
- LY3009120
Catalog No.:BCC3985
CAS No.:1454682-72-4
- 4-Benzoylpyridine
Catalog No.:BCC8697
CAS No.:14548-46-0
- PF-06463922
Catalog No.:BCC5568
CAS No.:1454846-35-5
- MRS 2179 tetrasodium salt
Catalog No.:BCC5685
CAS No.:1454889-37-2
- (2R,3S)-Boc-3-Phenylisoserine
Catalog No.:BCN8362
CAS No.:145514-62-1
- 1,7-Dimethoxy-2,3-methylenedioxyxanthone
Catalog No.:BCN7539
CAS No.:145523-71-3
- Mitiglinide Calcium
Catalog No.:BCC5000
CAS No.:145525-41-3
- Eucamalol
Catalog No.:BCN1648
CAS No.:145544-91-8
- Sophocarpine
Catalog No.:BCN5971
CAS No.:145572-44-7
- Cyclocommunol
Catalog No.:BCN3375
CAS No.:145643-96-5
- NNC 711
Catalog No.:BCC7176
CAS No.:145645-62-1